Document available in English, Spanish and French.
This document aims to support public health preparedness planning and response activities on the safe handling of bodies of deceased persons with suspected or confirmed COVID-19: at the site of death, during transport, storage and preparation before burial/cremation, and during burial/cremation.
This document provides guidance for African Union Member States on actions to be taken to ensure they continue to meet all the health
needs of their citizens in accordance with achieving the objectives of the Africa Health Strategy 2016 – 2030.
23 Dec 2020. The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, based on the experience in the EU from August–December, 2020. This document also addresses transmissio...n to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing and the efficacy of partial and full school closures. This document draws upon and updates evidence presented in the previous report from ECDC on this topic, which was published on August 6, 2020
more
This joint ECDC-European Union Aviation Safety Agency (EASA) document aims to support Member States in determining a coordinated approach to reduce the risks related to the movement of people by air within and between the EU/EEA countries and the UK in the context of the COVID-19 pandemic, noting th...at the impact of quarantine and testing is likely to vary according to levels of ongoing community transmission, and in the context of ECDC’s current advice that non-essential travel should be avoided during the end-of year festive period
more
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States.
Currently..., there is:
1. No scientific evidence from pre-clinical studies on the therapeutic effect of ivermectin for the management of COVID-19;
2. No evidence of its clinical efficacy for the management of patients with asymptomatic, mild, moderate or severe COVID-19; and
3. No safety data regarding the use of ivermectin for COVID-19 in the majority of the published studies.
more
24 Nov. 2021; This guidance provides considerations and a series of options that can be used to inform country strategies to minimise risk associated with shortages of personal protective equipment (PPE).
Re-use and reprocessing of single use PPE must be a last-resort temporary measure that is impl...emented only until stocks are replenished (2).This remains an area of active research and further updates to this evidence base are anticipated.
more
Preparedness planning is essential in order to respond effectively to outbreaks, including single case occurrences of highconsequence infectious diseases (HCID), such as the importation of a viral haemorrhagic fever (VHF) case